Amifostine

Drug Overview

The medication known as amifostine (marketed under the brand name Ethyol) is a vital supportive care drug used in oncology. It is not a chemotherapy agent designed to kill cancer; rather, it is a “cytoprotective” drug. Its primary job is to act as a biological shield, protecting healthy cells and organs from the toxic side effects of certain chemotherapies and radiation treatments.

In the clinical setting, amifostine is often called a “chemoprotectant” or “radioprotectant.” It is a specialized prodrug—meaning it is inactive when first given and only turns into its protective form once it reaches the body’s healthy tissues.

• Generic Name: Amifostine.
• US Brand Names: Ethyol.
• Drug Class: Cytoprotective Agent / Radioprotectant / Chemoprotectant.
• Route of Administration: Intravenous (IV) infusion or Subcutaneous (under the skin) injection.
• FDA Approval Status: FDA-approved to reduce kidney toxicity from cisplatin in lung cancer and to reduce dry mouth (xerostomia) caused by radiation in head and neck cancer.

What Is It and How Does It Work? (Mechanism of Action)

Amifostine is a “Smart Drug” that can tell the difference between a healthy cell and a cancer cell based on the pH of the environment. To understand how it works at the molecular level, we must look at how it transforms inside the body.

The Conversion into WR-1065

Amifostine is an organic thiophosphate. Once injected into the blood, it travels to the tissues where an enzyme called alkaline phosphatase (found in high amounts on healthy blood vessels) strips away the phosphate group. This turns the drug into its active form, known as WR-1065.

Molecular Level Mechanisms

1. Free Radical Scavenging: WR-1065 is a powerful antioxidant. When radiation or chemotherapy (like cisplatin) enters the body, they create “free radicals”—unstable molecules that rip apart DNA. WR-1065 acts like a sponge, soaking up and neutralizing these radicals before they can damage healthy DNA.
2. Selective Protection: Healthy tissues have a neutral pH and high levels of alkaline phosphatase, which activates the drug quickly. Cancer cells, however, are typically acidic and have poor blood flow, meaning they do not activate the drug as well. This allows the drug to protect your healthy organs while leaving the cancer vulnerable to the treatment.
3. DNA Repair Acceleration: Research shows that amifostine can bind to DNA and speed up the natural repair process in healthy cells that have been “nicked” by radiation.
4. Oxygen Depletion Prevention: By protecting the tiny blood vessels (capillaries) from radiation damage, amifostine ensures that healthy tissues continue to receive oxygen and nutrients during treatment, preventing long-term scarring (fibrosis).

FDA-Approved Clinical Indications

Amifostine is used specifically to prevent “collateral damage” during aggressive cancer treatments.

Oncological Uses:

• Reduction of Renal Toxicity: FDA-approved to protect the kidneys in patients receiving repeated doses of cisplatin for advanced non-small cell lung cancer (NSCLC).
• Reduction of Xerostomia (Dry Mouth): FDA-approved to protect the salivary glands in patients undergoing post-surgery radiation for head and neck cancer.
• Prevention of Neutropenia: Used in some settings to protect bone marrow and keep white blood cell counts higher during chemotherapy.

Non-oncological Uses:

• There are currently no standard non-oncological uses for amifostine.

Dosage and Administration Protocols

Amifostine is usually given as a quick infusion shortly before the actual cancer treatment begins.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) highlights how amifostine improves a patient’s quality of life during and after treatment.

• Salivary Gland Protection: Clinical trials show that patients using amifostine during radiation are 50% less likely to suffer from severe, permanent dry mouth. This allows patients to swallow, speak, and taste food much better after their cancer journey.
• Kidney Safety: In patients receiving cisplatin, the use of amifostine has been shown to reduce the risk of permanent kidney damage by over 30%, allowing patients to complete their full course of chemotherapy without needing dialysis.
• Long-Term Survival: Studies confirm that amifostine protects healthy cells without protecting the tumor. Research across thousands of patients shows no reduction in the cancer-killing power of radiation or chemotherapy when amifostine is used.

Safety Profile and Side Effects

While amifostine is a protective drug, it can cause temporary but significant side effects during the infusion itself.

Common Side Effects (>10%):

• Hypotension (Low Blood Pressure): The most common side effect. Patients may feel dizzy or faint during the IV.
• Severe Nausea and Vomiting: Amifostine is known to cause significant stomach upset, often more than the chemotherapy itself.
• Flushing: A warm, red feeling in the face and neck.
• Sneezing and Runny Nose: A common reaction during the infusion.

Serious Adverse Events:

• Severe Skin Reactions: Rare cases of Erythema Multiforme or Stevens-Johnson Syndrome have been reported.
• Hypocalcemia: A temporary drop in calcium levels in the blood.
• Black Box Warning: There is no FDA Black Box Warning, but there is a Major Warning regarding blood pressure and serious skin rashes.
• Management Strategies: To prevent nausea, patients are given powerful anti-sickness meds (like Ondansetron) before the infusion. To manage blood pressure, patients must be well-hydrated with IV fluids and must lie down during the infusion.

Research Areas

In the world of Stem Cell and Regenerative Medicine, amifostine is being studied as a “niche protector.” When patients undergo bone marrow transplants, their “stem cell niche” (the home where new blood cells grow) is often damaged by radiation. Researchers are testing if amifostine can protect these microscopic homes. By keeping the bone marrow environment healthy, amifostine may help transplanted stem cells “engraft” (start growing) much faster, leading to a quicker recovery of the immune system.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Blood Pressure Check: Baseline vitals must be stable.
• Calcium Levels: To ensure the patient isn’t at risk for hypocalcemia.
• Hydration Check: The patient must be adequately hydrated before the dose.

Precautions During Treatment:

• Lie Flat: You must remain lying down during the infusion and for about 5–10 minutes afterward to prevent fainting.
• Medication Review: Tell your doctor if you take blood pressure medicine, as you may need to stop it for 24 hours before your amifostine dose.

“Do’s and Don’ts” List:

• DO drink plenty of water the day before your treatment.
• DO report any new skin rash, even a small one, to your doctor immediately.
• DON’T stand up quickly after your infusion.
• DON’T skip your anti-nausea medications, even if you feel fine.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Amifostine is an FDA-approved prescription medication. Always consult with a qualified oncologist or healthcare professional regarding your specific treatment plan, potential side effects, and the management of complications during therapy.